Your browser doesn't support javascript.
loading
Cost-effectiveness of physical activity in the management of COPD patients in the UK.
Ramos, Mafalda; Lamotte, Mark; Gerlier, Laetitia; Svangren, Per; Miquel-Cases, Anna; Haughney, John.
Afiliação
  • Ramos M; Real World Evidence Solutions, IQVIA, 1930 Zaventem, Belgium, mafalda.ramos@iqvia.com.
  • Lamotte M; Real World Evidence Solutions, IQVIA, 1930 Zaventem, Belgium, mafalda.ramos@iqvia.com.
  • Gerlier L; Real World Evidence Solutions, IQVIA, 1930 Zaventem, Belgium, mafalda.ramos@iqvia.com.
  • Svangren P; Core Respiratory, Global Product and Portfolio Strategy - Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, SE-431 83 Mölndal, Sweden.
  • Miquel-Cases A; Global Price and Reimbursement, Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, Cambridge CB2 8PA, UK.
  • Haughney J; Academic Primary Care Division of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK.
Article em En | MEDLINE | ID: mdl-30697043
BACKGROUND: While the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines advise exercise to reduce disease progression, little investment in promoting physical activity (PA) is made by health care authorities. The purpose of this study was to estimate the cost-effectiveness of regular PA vs sedentary lifestyle in people with COPD in the UK. METHODS: Efficacy, quality of life, and economic evidence on the PA effects in COPD patients were retrieved from literature to serve as input for a Markov microsimulation model comparing a COPD population performing PA vs a COPD population with sedentary lifestyle. The GOLD classification defined the model health states. For the base case, the cost of PA was estimated at zero, a lifetime horizon was used, and costs and effects were discounted at 3.5%. Analyses were performed from the UK National Health Service (NHS) perspective. Uncertainty around inputs and assumptions were explored via scenario and sensitivity analyses, including a cost threshold analysis. Outcomes were cost/quality-adjusted life year (QALY) gained and cost/year gained. RESULTS: Based on our model, the effects of PA in the UK COPD population would be lower mortality (-6%), fewer hospitalizations (-2%), gains in years (+0.82) and QALYs (+0.66), and total cost savings of £2,568. The cost/QALY and cost/year gained were dominant. PA was cost-saving at costs <£35/month and cost-effective at cost <£202/month. The main model drivers were age and PA impact on death and hospital-treated exacerbations. CONCLUSION: Including PA in the management of COPD leads to long-term clinical benefits. If the NHS promotes only exercise via medical advice, this would lead to health care cost savings. If the NHS chose to fund PA, it would still likely be cost-effective.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exercício Físico / Custos de Cuidados de Saúde / Doença Pulmonar Obstrutiva Crônica / Comportamento de Redução do Risco / Estilo de Vida Saudável / Promoção da Saúde / Pulmão Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Exercício Físico / Custos de Cuidados de Saúde / Doença Pulmonar Obstrutiva Crônica / Comportamento de Redução do Risco / Estilo de Vida Saudável / Promoção da Saúde / Pulmão Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Health_economic_evaluation / Prognostic_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Revista: Int J Chron Obstruct Pulmon Dis Ano de publicação: 2019 Tipo de documento: Article